After J.P. Morgan and SunTrust Robinson gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics today and set a price target of $120.00. The company’s shares closed last Monday at $48.05.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -16.6% and a 24.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $97.50 average price target.
See today’s analyst top recommended stocks >>
Based on Global Blood Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $57.32 million. In comparison, last year the company had a GAAP net loss of $43.07 million.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
